Bio News
Daewoong Pharmaceutical’s botulinum toxin Nabota has completed its launch in seven Middle Eastern countries with its entry into Kuwait, setting a record for the widest regional presence among Korean companies. Daewoong Pharmaceutical will begin marketing in Kuwait, a market valued at 24 billion won, with a launch symposium for about 200 attendees in October. The company plans to use Kuwait as a hub in the Middle East, expand its sales and academic activities, and strengthen its efforts to target the GCC market.
BIOBOOK TEAM
biobookmedia@biobook.co.krParagon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug
Formycon and Zydus’ Keytruda Biosimilar Is First to Be Accepted for FDA Review
Pfizer Signs $500 Million Protein Degrader Deal With Enodia
